Prescription RequiredRIBOCICLIB 200 mg (Kryxana) is a prescription targeted anticancer medication used to treat hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. It belongs to a class of medicines called CDK4/6 inhibitors and is typically used in combination with hormone therapy to help slow the growth and spread of cancer cells. Treatment should be supervised by an oncologist.
| Generic name | RIBOCICLIB |
| Strength | 200 mg |
| Manufacturer | NOVARTIS |
| Package size | 21 Tablets |
| Used for | Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Ribociclib 200 mg works by blocking cyclin-dependent kinases 4 and 6 (CDK4/6), enzymes that regulate cell division. By inhibiting these proteins, it prevents cancer cells from multiplying, slowing tumor growth and helping control the progression of HR-positive, HER2-negative breast cancer.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.
